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Abstract Survivin is a well-established target in experi-
mental cancer therapy. The molecule is over-expressed in
most human tumors, but hardly detectable in normal tis-
sues. Multiple functions in different subcellular compart-
ments have been assigned. It participates in the control of
cell division, apoptosis, the cellular stress response, and
also in the regulation of cell migration and metastasis.
Survivin expression has been recognized as a biomarker:
high expression indicates an unfavorable prognosis and
resistance to chemotherapeutic agents and radiation treat-
ment. Survivin is an unconventional drug target and several
indirect approaches have been exploited to affect its
function and the phenotype of survivin-expressing cells.
Interference with the expression of the survivin gene, the
utilization of its messenger RNA, the intracellular locali-
zation, the interaction with binding partners, the stability of
the survivin protein, and the induction of survivin-specific
immune responses have been taken into consideration. A
direct strategy to inhibit survivin has been based on the
identification of a specifically interacting peptide. This
peptide can recognize survivin intracellularly and cause the
degradation of the ligand–survivin complex. Technology is
being developed that might allow the derivation of small
molecular-weight, drug-like compounds that are function-
ally equivalent to the peptide ligand.
1 Introduction
1.1 Progress in Tumor Therapy and Properties
of Desirable Drug Targets
Progress in prevention and therapy has led to remarkable
decreases in mortality and death rates due to cancer.
Between 1990 and 2008, the death rates declined by
15.1 % in women and 22.9 % in men [1, 2]. Preventive
measures, extensive screening programs for breast and
colon cancer, and the development of new and effective
drugs contributed to these reductions. Studies of the genetic
basis of cancer, insights into the regulation of signaling
pathways and their biochemical components, understand-
ing the communication between cancer cells and normal
cells, and the elucidation of the mechanisms of metastasis
are areas in which basic research has made remarkable
progress. This knowledge led to the identification and
exploitation of new and promising drug targets. Molecu-
larly targeted therapies, aimed at individual signaling
components activated in cancer cells, have improved the
success of treatment [3, 4].
Following the pioneering example set by the inhibition
of the Abelson kinase in chronic myelogenous leukemia
patients [5], most of these targeted drugs have been
directed against protein kinases that are aberrantly acti-
vated in particular cancer cells. The combined treatment of
metastatic melanoma patients with selective B-Raf and
mitogen-activated protein extracellular kinase (MEK)
inhibitors significantly improved their progression-free
survival [6]. An inhibitor of ALK (the anaplastic lym-
phoma kinase) caused durable responses in patients with
ALK-positive non-small-cell lung cancer [7]. Patients with
myeloproliferative disease benefited from treatment with
Janus kinase 2 (JAK2) inhibitors [8] and B-cell
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hematologic malignancies responded favorably to the
inhibition of the phosphatidylinositide 3-kinase (PI3K)
p110d isoform [9].
Not only kinase inhibitors, but also monoclonal anti-
bodies have become most effective in cancer treatment.
Antibodies directed against the epidermal growth factor
(EGF) receptor family initially showed the benefit of this
class of molecules for cancer therapy [10]. In the mean-
time, combinations of monoclonal antibodies and conven-
tional chemotherapeutic agents have improved treatment
[11] and additional, valuable targets and drug combinations
are being exploited. For example, an antibody directed
against the cytotoxic lymphocyte antigen CTLA4 caused
the reactivation T-cell cytolytic activity against melanoma
cells [12] and the combination of antibodies and kinase
inhibitors is being used in breast cancer patients [13]. The
inhibitor of the hedgehog signaling pathway, vismodegib,
resulted in very favorable responses in patients with locally
advanced and metastatic basal cell carcinoma [14].
Despite the impressive success achieved with the drugs
described above, a large number of promising drug targets
have not yet been exploited and offer opportunities for
future progress. This holds for many of the oncogenes and
tumor suppressors that have been known for many years
and which became the foundations of molecular oncology.
Mutated versions of, for example, tumor-suppressor protein
p53 (TP53), K-Ras, and N-Ras are recognized drivers of
transformation in a large number of cancer entities, but
targeted drugs exploiting these genetic aberrations are not
yet available. The same is true for transcription factors that
drive the transformed phenotype, e.g., MYC, N-MYC,
signal transducer and activator of transcription 3 (Stat3)
and Stat5, and a variety of docking molecules and adapters
which play crucial roles in the assembly of high molecular-
weight protein complexes. The development of drugs tar-
geting such oncogenic proteins, proteins with an intracel-
lular location and no enzymatic activity, will depend on the
development of methods that allow the exploitation of
defined protein–protein interactions (PPIs). The disruption
of such interactions poses conceptional and technological
challenges. A number of encouraging examples, however,
show that such an approach is feasible and useful [15–19].
It involves steps that are ‘‘non-conventional’’ in current
drug development protocols [20], but it is clearly worth-
while pursuing. Many more, functionally essential onco-
proteins could thus become useful drug targets.
1.2 Extending the Range of Useful Drug Targets
The development of drugs usually depends upon suitable
drug targets, which meet defined structural prerequisites.
Drug target structures are preferably molecules that contain
binding pockets for known low molecular-weight
compounds. These compounds can serve as leads and
structural analogs can be derived that recognize the same
site. They can function as competitive or irreversibly
binding inhibitors for naturally occurring ligands. The
number of drug targets which fulfill these requirements are
limited and additional drug target structures have to be
explored and exploited. The functions of intracellular sig-
nal transduction components usually rely on specific
interactions of particular protein domains, and are often
regulated by secondary modifications. They propagate
extracellular signals through the cytoplasm and into the
nucleus and participate in transcription, translation, and
organelle function. Aberrations in the regulation of the
formation or disassembly of protein complexes are reasons
for pathologic conditions. Conversely, the targeted inter-
ference with interactions of proteins or the interactions of
proteins with DNA, important, for example, for the sur-
vival and proliferation of tumor cells, can be used for drug
discovery and development.
Cancer cells harbor multiple genomic and epigenetic
abnormalities. They also show the persistent activation of
particular signaling pathways which are only transiently
active in normal cells. These enhanced and prolonged
signaling events can result in the dependence on particular
activated signaling components for survival and growth
[21]. The downregulation or functional inhibition of such
molecules often results in the arrest of proliferation or the
induction of apoptosis of tumor cells. A number of proteins
and protein complexes which are indispensable for the
growth and survival of cancer cells, components to which
tumor cells are addicted, have been identified. RNA
interference (RNAi) experiments can be carried out to
downregulate such molecules and verify that they are
indispensable in the context of particular cultured tumor
cells [22]. They appear most suited as drug targets, and
survivin belongs to this class of molecules. Since survivin
fits the description of a non-conventional drug target,
indirect strategies have been employed to interfere with its
function. They are based on the inhibition of transcription
of the survivin gene, interference with survivin messenger
RNA (mRNA) utilization, the folding or the stability of the
survivin protein, its secondary modifications and intracel-
lular localization [23–25]. However, additional efforts are
underway to develop drugs that directly interact with sur-
vivin and inhibit its functions, i.e., survivin-specific ligands
with inhibitory potential [26]. These strategies have been
summarized in Fig. 1.
2 Literature Search
A literature search of the biomedical literature was per-
formed via PubMed up to June 2013 using the following
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terms: survivin, survivin cancer, survivin review, survivin
apoptosis, survivin inhibitor.
3 Properties of Survivin and the Rationale
for Targeting Survivin in Cancer Therapy
Survivin is a regulatory protein of 142 amino acids and a
member of the family of inhibitors of apoptosis proteins
(IAPs) [27]. A transcript and four-splice variants have been
detected. The protein is distinguished by a single
baculovirus IAP repeat (BIR) domain, but lacks the RING
(really interesting new gene)-finger domain and the cas-
pase-associated recruiting domain (CARD) present in other
members of the IAP family. It assumes versatile functional
roles and participates in the control of cell division,
apoptosis, the cellular stress response, and also cell
migration and metastasis [28–30].
Survivin has an intriguing expression pattern. It is
expressed and required for normal fetal development, but it
is not present in most adult tissues, exceptions being vas-
cular endothelial cells and hematopoietic cells [31]. The
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Fig. 1 Interference with the biogenesis and the function of survivin
[26]. The majority of the strategies employed to inhibit survivin are
based on insights into the regulation of its synthesis and processing.
Transcription factors have been identified which interact with and
regulate the transcription of the survivin gene. Specific inhibitors for
these transcription factors, e.g., ILF3/p54(nrb), Sp1, Stat3, and NF-
jB, have been used to downregulate survivin mRNA expression.
Upon transcription, the stability and utilization of survivin mRNA can
be modulated by molecules able to form double-stranded nucleic
acids. Antisense oligonucleotides, siRNA, and miRNA can cause the
degradation of survivin mRNA or impede its translation into protein.
Several signal transduction pathways are able to affect the stability of
the survivin protein through the regulation of E3 ligases and
proteasomal degradation. Especially the EGFR pathway and its
downstream effectors can be used to manipulate survivin levels. The
only molecule whose inhibitory action is based on its direct
interaction with survivin is rSip. This molecule is comprised of a
survivin interaction domain derived from the ferritin heavy chain.
Intracellular binding to survivin causes its degradation and functional
inhibition [26]. The proper folding of survivin is dependent upon the
chaperone protein HSP90. Its function can be inhibited by geldana-
mycin and shepherdin, and the subcellular localization of survivin can
be manipulated through the interference with kinases and protein
acetylases. Finally, survivin-expressing cells can be eliminated
through the induction of specific cytotoxic killer cells. CBP cyclic
adenosine monophosphate response element-binding protein, DC
dendritic cell, EGFR epidermal growth factor receptor, ERK extra-
cellular signal-regulated protein kinase, HDAC histone deacetylase,
HSP heat shock protein, ILF interleukin enhancer-binding factor,
MEK mitogen-activated protein extracellular kinase, miRNA microR-
NA, mRNA messenger RNA, NF-jB nuclear factor kappa B, PLK-1
polo-like kinase-1, rSip recombinant survivin interacting protein,
siRNA small interfering RNA, Sp1 specificity protein 1, Stat signal
transducer and activator of transcription
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survivin gene is positively regulated by transcription fac-
tors such as b-catenin/TCF-Lef, hypoxia-inducible factor
1-a (HIF1a), specificity protein 1 (Sp1) and Stat3, and
negatively by the tumor suppressor genes p53, Rb, and
PTEN (phosphatase and tensin homolog) [32]. The survivin
protein is post-translationally modified by the polo-like
kinase-1 (PLK-1), the aurora B kinase and p34cdc2/cyclin
B, and is also regulated through ubiquitination [33].
Survivin is present in different subcellular compart-
ments, in the cytosol, the mitochondria and the nucleus,
and exerts distinct cellular functions in those compart-
ments. The nuclear survivin is active in the regulation of
mitosis and contributes as a chromosomal passenger
complex protein to the proper alignment of chromosomes,
chromatin-associated spindle formation and kinetochore
microtubule attachment [34]. In its acetylated form, it also
participates in the formation of transcription complexes
[35]. As a regulator of apoptosis in the cytoplasm, sur-
vivin interacts with and stabilizes phosphorylated
X-linked inhibitor of apoptosis protein (XIAP), and
inhibits caspase-3 and caspase-9. In the mitochondria it
sequesters pro-apoptotic Smac (second mitochondria-
derived activator of caspases) and prevents its release into
the cytoplasm [36].
When normal cells and tumor cells were compared, the
selective expression pattern of survivin attracted the
attention of tumor biologists. No or very little survivin was
found in normal tissues, but strong expression was asso-
ciated with nearly all cancer tissues [37]. Survivin
expression in tumor cells could possibly be induced by Wnt
and mammalian target of rapamycin (mTOR) signaling
[38, 39]. The loss of tumor suppressor proteins and the
activation of oncoproteins probably cooperate in the
upregulation of survivin in cancer cells. The over-expres-
sion of survivin promoted the survival of aneuploid cells
[40], blocked caspase-dependent and -independent cell
death, increased proliferation, and increased angiogenesis
[24]. It also correlated with therapy resistance and unfa-
vorable prognosis in many tumor entities [41, 42].
A number of studies have addressed the consequences of
interference with survivin expression or function in tumor
cells. The introduction of a dominant negative variant of
survivin into prostate and cervical cancer cells caused the
formation of multipolar mitotic spindles, failure of cyto-
kinesis, the formation of multinucleated cells, and resulted
in reduced proliferation and the induction of apoptosis [43].
The essential contribution of survivin for the survival of
cancer cells was corroborated by RNAi experiments and
confirmed its potentially valuable role as a drug target.
Downregulation of survivin efficiently inhibited tumor cell
growth [26] and increased treatment-induced apoptosis of
cancer cells [44, 45].
4 Pharmacologic and Genetic Approaches to Interfere
with Survivin Function
After it became clear that survivin is a promising thera-
peutic target in cancer, efforts have been made to develop
strategies and compounds able to functionally interfere
with this molecule. These efforts, however, have been
hampered by the structural properties of survivin, which
initially put survivin into the category ‘‘non-druggable’’.
Nevertheless, a number of approaches for survivin inhibi-
tion have been employed which are based on indirect
mechanisms, e.g., interference with the expression of the
survivin gene, the utilization of its mRNA, the intracellular
localization, the interaction with binding partners, the sta-
bility of the survivin protein, and the induction of survivin-
specific immune responses (Fig. 1).
4.1 Interference with Survivin Gene Transcription
Several transcription factors are known which recognize
specific response elements in the survivin gene promoter
and are involved in the regulation of survivin mRNA
transcription. Blocking transcription of the survivin gene
through the inhibition of specific transcription factors
seems to be an attractive concept to interfere with survivin
function. YM155 (sepantronium bromide) was selected in a
screen of a compound library as an inhibitor of a survivin
promoter-reporter gene construct [46]. The compound was
also able to suppress survivin expression in cultured cells
and in transplanted PC-3 tumor cells in mice. This resulted
in the inhibition of tumor growth. The promising animal
experiments led to clinical studies in patients with
advanced solid tumors in which favorable responses were
observed [47]. The beneficial effects of YM155 were fur-
ther underlined by enhancing the effects of docetaxel in
malignant melanoma cells [48], by reversing the cis plati-
num resistance in head and neck cancer cells [49], by
downregulating EGF receptor expression and its down-
stream effector pathways in pancreatic cancer cells [50],
and by potentiating the function of the Bcl-2/Bcl-xL
inhibitor ABT-737 in human glioma cells [51].
The mechanism of YM155 action in the negative reg-
ulation of the survivin gene has been the cause of a recent
controversy. The induction of DNA damage by YM155
rather than the transcriptional repression has been proposed
as the primary effect of the drug [52]. Additional evidence
for a transcription-mediated mode of action, however, has
come from experiments which showed that the survivin
promoter is regulated by a complex of p54(nrb) and the
transcription factor, interleukin enhancer-binding factor 3
(ILF3). p54(nrb) recognizes a specific sequence in the
survivin promoter. YM155 binds directly to (ILF3)/NF110
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[53], induces the disruption of the ILF3/p54(nrb) complex,
and results in transcriptional silencing [54].
Additional transcription factors and inhibitory com-
pounds have been used to interfere with survivin gene
transcription. Tetra-O-methyl nordihydroguaiaretic acid
(M4N) has been described as a transcriptional repressor of
the survivin promoter. M4N is not survivin gene specific,
but seems to repress genes dependent on the Sp1 tran-
scription factor. M4N treatment of glioblastoma cells
decreased the cell proliferation, enhanced the effects of the
chemotherapeutic agent temozolomide (TMZ) and radia-
tion, induced apoptotic cell death, decreased the mitotic
index, and arrested the cell cycle in the G2/M phase [55].
Stat3 has been recognized as a potential therapeutic
target for some time. This transcription factor regulates a
number of transformation-associated target genes and its
inhibition results in tumor cell death [56]. The small
molecular weight inhibitor S3I-1757 is capable of dis-
rupting Stat3 dimerization, prevents Stat3-mediated trans-
activation and suppresses the expression of target genes,
e.g. survivin, but also Bcl-xL, cyclin D1, and MMP9
(matrix metallopeptidase 9). This results in the inhibition
of tumor cell growth, migration, and invasion [57, 58]. The
transcription factor Sox2 is also directly involved in the
regulation of survivin gene transcription. Sox2 downregu-
lation results in a decrease in survivin expression, caspase-
9 activation, and initiation of mitochondria-dependent
apoptosis. Agents interfering directly with Sox2 transacti-
vation could therefore possibly become of interest as
modulators of survivin expression [59].
Other compounds exerting their effects on survivin
expression, indirectly by interference with transcription
factors, are histone deacetylase (HDAC) inhibitors. Treat-
ment of tumor cells with belinostat resulted in the down-
regulation of survivin on the mRNA and protein level,
possibly through increased expression of transforming
growth factor beta receptor II (TGFbRII) [60].
Finally, it has been shown that caspase-2 represses
transcription of the survivin gene through the caspase-2-
mediated proteolytic cleavage of the nuclear factor kappa B
(NF-jB) activator, receptor-interacting protein 1 (RIP1).
Degradation of RIP1 prevents transcription of NF-jB tar-
get genes, among them survivin. This counteracts NF-jB-
dependent cell survival and results in deregulated mitotic
transitions, enhanced apoptosis, and suppression of
tumorigenicity [61].
4.2 Interference with Survivin Messenger RNA
Utilization Through Antisense Oligonucleotides,
Small Interfering RNA, and MicroRNA
Inhibition of specific transcription factors, as described
above, can lead to a decrease in survivin mRNA and
depletion of the survivin protein. A similar effect can also
be achieved through interference with survivin mRNA
utilization. Antisense oligonucleotides (ASOs), small
interfering RNA (siRNA) and micro RNA (miRNA) can
serve this purpose.
Oligonucleotides complementary with human survivin
mRNA have been synthesized. These ASOs contain a
phosphorothioate backbone and 20-MOE (20-O-methoxy
ethyl/phosphorothioate) modifications of the ribose of the
first four and last four nucleotides of the ASO, which
enhances the affinity for target RNA, increases the plasma
stability, and decreases toxicity when compared with ear-
lier compounds. When ASOs are introduced into cells, they
bind to their complementary target mRNA and cause their
degradation through the activity of RNase H or they inhibit
the mRNA utilization and translation into proteins. The
survivin-directed ASO, LY2181308, a product of second-
generation chemistry, potently inhibited expression of
survivin when it was introduced into tumor cells. It caused
the induction of caspase-3 activity and arrested cell divi-
sion. LY2181308 was also active in vivo when adminis-
tered intravenously in human xenograft mouse models. It
inhibited tumor growth and enhanced the effects of gem-
citabine, paclitaxel, and docetaxel [62].
EZO-3042 is another ASO directed against survivin. It is
based on an engineered O20 to C40 linkage within the ribose
sugar which locks the molecule in the 30-endo structural
conformation favoring RNA binding. This 16mer targets
the region of the stop codon of the open reading frame and
EZN-3042 introduction into cells resulted in a strong
downregulation of survivin mRNA and growth inhibition
of cultured tumor cells [63]. These ASOs are being eval-
uated in combination with chemotherapeutic drugs in
clinical trials [24, 25].
Post-transcriptional gene silencing by RNAi is an
effective tool to verify drug targets and will find its place in
cancer therapy. siRNA is more effective than antisense
RNA or ASO and has a remarkable target specificity.
siRNA specific for survivin has been delivered into target
cells in culture and has shown its effectiveness in a range of
cancer cell lines from different indications [56, 64–66]. It
not only caused polyploidy, growth arrest and apoptosis,
but also increased the sensitivity of the cells towards che-
motherapeutic agents. Delivery of survivin siRNA in vivo
is still technically challenging, but the application of
polyethylenimine (PEI)/siRNA complexes have been
shown to be able to downregulate survivin in mice and
have yielded promising therapeutic results in animals
transplanted with glioma cells [64].
Survivin mRNA seems to be a target for miR-34a. miR-
34a negatively regulates survivin protein expression and
thus is able to inhibit gastric cancer cell proliferation and
invasion. Silencing the survivin gene in tumor cells via the
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upregulation of miR-34a might become a strategy of the
future [67].
4.3 Interference with Signaling Pathways Regulating
Survivin Gene Expression
Signaling pathways regulate cytoplasmic kinase cascades
and transcription factor activities and subsequently
change gene expression patterns. The signaling potential
of multiple growth factors is mediated through effector
molecules such as PI3K/AKT, extracellular signal-regu-
lated protein kinases 1/2 (ERK1/2), c-Jun N-terminal
kinase (JNK) and JAK/Stat3, and governs survival and
proliferation of normal and of tumor cells. Survivin is a
target of EGF signaling in cancer cells. EGF-mediated
induction of survivin requires the activity of Raf-1 and
MEK/ERK, but EGF has no significant effect on survivin
transcription. It prolongs the half-life of the survivin
protein and stabilizes it by inhibiting survivin ubiquiti-
nation [68]. Many antibodies and small molecular-weight
compounds aimed at members of the EGF receptor
family and its downstream effectors are registered drugs
or in clinical development [69]. These drugs might exert
some of their functions through the destabilization of
survivin.
A similar mechanism might be responsible for the high
levels of survivin expression in human tumors harboring
mutant K-Ras. Depletion of K-Ras in such tumor cells
causes a decrease in survivin levels, following ubiquiti-
nation and proteasomal degradation of survivin, and
impedes anchorage-independent growth, invasion, and
survival of the tumor cells [70]. Inhibitors of downstream
effectors of K-Ras might be able to induce similar phe-
notypes. The leukemic fusion protein BCR-ABL induces
survivin expression at both the mRNA and protein levels
and inhibits the apoptotic regulation in chronic myeloid
leukemia cells. BCR-ABL-mediated upregulation of sur-
vivin requires JAK2/Stat3 activation [71]. Specific
inhibitors for these signaling components are also avail-
able [19, 58]. Wogonin, a plant flavonoid compound,
activates ERK and caspases in MCF-7 cells, but blocks
the PI3K/Akt/survivin signal pathway, thus causing a pro-
apoptotic effect [72].
Not all signaling pathways necessarily lead to the
induction of survivin levels. The mTOR protein is being
explored as a potential therapeutic target in cancer patients
and this signaling molecule seems to negatively regulate
survivin expression. The inhibition of mTOR with rapa-
mycin in neuroblastoma cells led to an induction in sur-
vivin mRNA and protein levels and the protection of these
cells against apoptosis. The beneficial and the counter-
productive effects of mTOR inhibitors in particular tumor
cell settings have to be carefully balanced [73].
4.4 Interference with Secondary Modifications
of Survivin Regulating its Subcellular Locations
and Distinct Functional Properties
The distinguishable functions of survivin in individual sub-
cellular compartments are most likely realized through the
domain structure of the molecule and regulated by secondary
modifications. The modifying enzymes are potential targets
for designed interference with distinct survivin functions, and
survivin sequestration in particular subcellular compartments
can possibly be exploited. Survivin is present in the cyto-
plasm, the mitochondria, and the nucleus. It performs distinct
functions in these subcellular compartments. Survivin can
inhibit both the extrinsic and the intrinsic pathways of
apoptosis induction by interference with the activation of
caspases in the cytoplasm and in mitochondria. In the
nucleus, it can form a complex with chromosomal passenger
proteins, e.g., Aurora-B kinase, inner centromere protein
(INCENP), and Borealin to regulate cell division. The par-
ticular subcellular location and the assumption of specific
functional properties are regulated by the domain structure
and signal-dependent secondary modifications of the protein.
Survivin is phosphorylated at threonine 117 by the Aurora-B
kinase. This directs survivin to the centromere and regulates
the assembly of the chromosomal passenger complex. Aur-
ora-B kinase activation is preceded by phosphorylation at
serine 20, which is catalyzed by PLK-1, and both phosphor-
ylation events are required for the correct spindle microtubule
attachment. Phosphorylation at threonine 34 is critical for the
anti-apoptotic function of survivin [74].
The nuclear accumulation of survivin is dependent upon its
acetylation on lysine 129 by cyclic adenosine monophosphate
response element-binding (CREB)-binding protein (CBP).
Survivin acetylation results in its homodimerization. The non-
acetylated form of survivin heterodimerizes with CRM1, and
thus becomes destined for nuclear export [35].
HDAC6 is responsible for reversing CBP-mediated
survivin acetylation. HDAC6 binds to and deacetylates
survivin. The relative concentrations of acetylated and non-
acetylation survivin at lysine 129 determine its interaction
with CRM1, and thus regulate the nuclear export of sur-
vivin [75]. Nuclear survivin also interacts with Stat3 and
represses the Stat3 transactivation potential [35]. The
modifying enzymes are potential targets for designed
interference with the diverse survivin functions. The
sequestration in particular subcellular compartments can be
envisaged [76].
4.5 Interference with Survivin Folding, Stability,
and Interaction Partners
Heat shock proteins (HSPs) are molecular chaperones that
assist in the folding and the assumption of a stable
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conformation of proteins. They prevent the formation of
protein aggregates. HSPs are often over-expressed in tumor
cells. HSP90 is a member of this gene family and an
essential adenosine triphosphatase-dependent molecular
chaperone. It assists in protein folding and quality control,
maturation of client proteins, and protein trafficking among
subcellular compartments. It is also involved in the sta-
bilization of client proteins which regulate apoptosis, pro-
liferation, autophagy, and cell cycle progression. Inhibitors
of HSP90 have been developed that can simultaneously
modulate several intracellular regulatory pathways [77].
Because of its restricted repertoire of client proteins, typ-
ically kinases and signaling molecules, HSP90 occupies a
unique position in cellular homeostasis [78].
Survivin is a HSP90 client protein and the interaction
domains between the two proteins have been exploited to
derive inhibitory molecules. Shepherdin is an oligopeptide
that comprises the survivin sequences from lysine 79 to
glycine 83, coupled to a protein transduction sequence
allowing the uptake of the molecule into cells. Shepherdin
binds to HSP90, inhibits the formation of the survivin
HSP90 complex, and competes with adenosine triphos-
phate binding to HSP90. Upon its uptake into, for example,
acute myeloid leukemia cells, it induced cell death in a
large fraction of the transduced cells. It also inhibited the
growth of transplanted tumor cells in mice [79]. Treatment
of glioblastoma cells with shepherdin caused the irrevers-
ible collapse of mitochondria, degradation of HSP90 client
proteins in the cytosol, and tumor cell killing. Targeting the
HSP90 functions in different subcellular compartments
could become therapeutically beneficial, at least partly
through its effects on survivin action [80].
4.6 Induction of Immune Responses Against Survivin-
Expressing Cells
Progress in understanding the molecular basis of cancer
etiology and insights into immunologic defense mecha-
nisms have led to promising new treatment options for
cancer patients [81, 82]. The enhancement of the immune
system has been validated as a promising therapeutic
strategy to elicit tumor-specific responses, induce durable
tumor regression, and improve survival intervals of patients
[83]. Tumor cells are poor antigen-presenting cells and the
induction of protective immunity depends upon efficient
tumor antigen presentation by activated dendritic cells.
They display surface antigens via major histocompatibility
complex class I and II in combination with co-stimulatory
molecules, e.g. B7-1 and B7-2, and are able to interact with
naı¨ve CD4? and CD8? T-cells to trigger T-cell prolifer-
ation and differentiation. Differentiated cytolytic CD8?
T-lymphocytes (CTLs) are the most important effector
cells for anti-tumor immune responses. Survivin is a tumor-
associated antigen (TAA) and therefore a potential target
for immunotherapy. Its immunogenicity was indicated by
the presence of survivin-specific CD8? T-cells and survi-
vin-specific IgG antibodies in cancer patients [84], and
HLA class II restricted epitopes have been identified.
Survivin-derived epitopes have been used in vaccination
experiments to activate CD4? responses in prostate cancer
[85] and melanoma patients [86]. Survivin-specific T-cell
activities were induced, which correlate with tumor
response and patient survival.
4.7 Interference with Survivin Function Through
Interacting Peptide Ligands
Survivin has been validated as a drug target by the
approaches described above [23–25, 87]. In particular, the
downregulation of survivin mRNA expression in tumor
cells with a lentiviral gene transfer vector encoding a
specific small hairpin RNA (shRNA) seems most con-
vincing [26]. Survivin has a favorable, tumor-preferential
expression profile, but it is a difficult drug target. Uncon-
ventional approaches have been used to exploit its
expression in tumor cells for therapeutic purposes. These
include the interference with survivin gene expression at
the transcriptional level, the inhibition of survivin mRNA
translation with ASOs and siRNA, the interference with
survivin functions through dominant negative variants of
the molecule and peptide antagonists, DNA vaccines and
immunotherapeutic strategies, and the use of small
molecular-weight compounds that target protein interac-
tions [30, 33, 60, 88, 89]. These strategies are based on
indirect mechanisms. They affect the expression and
eventually the function of the protein, but they are not
based on the direct binding of a drug to survivin.
An alternative strategy has recently been described
which exploits survivin-specific ligands to derive an
inhibiting molecule. The strategy employs the screening of
a complementary DNA (cDNA) library for surviving
interacting proteins in a yeast two hybrid setting. Several
survivin interaction partners have previously been descri-
bed, e.g. the pro-apoptotic protein Smac [88] and the
borealin component of the chromosomal passenger com-
plex [90], but a novel interacting protein, a domain of the
ferritin heavy chain 1 (FTH1) has been detected [26].
Ferritin is a widely expressed protein and can sequester
free intracellular iron. FTH1 embodies ferroxidase activity
and can convert Fe2? to the less reactive and less toxic
Fe3?. This function involves the coordinated activity of
ferritin heavy chain (FTH1) and ferritin light chain
subunits.
The survivin-interacting domain of FTH1 has been
integrated into a recombinant protein, rSip. This protein
was also provided with a protein transduction domain and
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tags which allow for the purification of the bacterially
expressed construct. Introduction of the purified protein
into survivin over-expressing breast cancer and glioma
cells, cells which express high levels of survivin, resulted
in survivin downregulation, decreased the growth and
viability of tumor cells in culture, and reduced growth of
the cancer cells upon transplantation into immunodeficient
mice. rSip selectively targets the anti-apoptotic function of
survivin and causes tumor cell death. The effects of
shSurvivin-induced downregulation of its mRNA or the
interference with survivin function by rSip are remarkably
specific to tumor cells. No growth inhibition and induction
of apoptosis were observed in non-transformed MCF-10A
and NIH/3T3 cells, they remained unaffected [26]. rSip, as
a peptide ligand of survivin, provides a lead structure for
the development of drugs targeting the tumor cell ‘‘addic-
tion protein’’ survivin.
The use of peptides to affect the induction of apoptosis
has previously been shown [91]. Peptides derived from the
pro-apoptotic Smac protein, another member of the IAP
family, are able to inhibit XIAP. This protein blocks cas-
pase activity and is over-expressed in cancer cells [92, 93].
Smac peptides, transduced into cells, induced tumor cell
apoptosis by inhibition of XIAP and the subsequent acti-
vation of caspases. Smac-TAT-peptides acted synergisti-
cally with TRAIL (tumor necrosis factor-related apoptosis-
inducing ligand), FasL, doxorubicin, or cisplatin in the
induction of apoptosis in malignant glioma cells [94]. The
experiments show that apoptosis induction in cancer cells,
dependent upon the over-expression of antiapoptotic pro-
teins such as XIAP or survivin, can be initiated by spe-
cifically interacting peptides, e.g., Smac-derived peptides
or rSip.
5 Prospective Tasks: Derivation of Small Molecular-
Weight Compounds from Peptide Ligands
Cell culture experiments have convincingly shown that
peptides and recombinant proteins have the ability to enter
cells and inhibit target protein functions through specific
binding interactions. These cell culture experiments, how-
ever, cannot easily be extrapolated to the in vivo situation.
Biologic macromolecules, nucleic acids, and polypeptides
have intrinsic properties that are unfavorable for their use
as systemically applied drugs [95]. Limitations arise from
their solubility, stability, toxicity, and ability to cross cell
membranes. The short half-life of the recombinant proteins
in the circulation of mice, often less than 10 min, precludes
that a lasting target inhibition, sufficient to exert, for
example, growth inhibitory and apoptotic effects. Experi-
ments have been carried out with intracellularly acting
peptides administered in a systemic fashion, and limited
therapeutic effects have been observed [96]. The dominant
negative survivin T34A mutant was produced as a
recombinant protein coupled to a protein transduction
domain and was found to be able to reduce melanoma cell
growth in experimental animals [97]. The growth of
transplanted glioma cells could only be partially inhibited
with a peptide targeting Stat3 [56].
For these reasons it seems reasonable to replace the
peptides by low molecular-weight compounds that exert
the same functional effects but exhibit better pharmacoki-
netic properties and bioavailability [20]. The peptides can
serve as tools in screening procedures designed to identify
such functional analogs. The screen can be based, for
example, on the disruption of the binding between survivin
and the FTH fragment. The availability of a peptide
sequence that functionally inactivates a crucial domain of
survivin can be exploited [26]. The peptide sequence can
serve as a tool in screening procedures that allow the
identification of small molecular-weight compounds,
which are functionally equivalent to the FTH1-derived
peptide sequence [98, 99]. The discovery of low molecular-
weight inhibitors of peptide–protein or PPIs is a most
important issue in modern drug development, one not
restricted to survivin research [100].
The procedure comprises the steps schematically
depicted in Fig. 2. Peptide sequences, which very spe-
cifically interact with essential domains of target proteins,
can be identified in yeast two hybrid screens [101].
Random peptide libraries of high complexity can be
employed and peptide ligands for target domains can be
identified regardless of structural considerations. The
mere interaction between the peptide ligand and the bait
domain of the target protein does not make predictions
about the functional consequences of the binding reaction.
The peptide sequences, however, can be validated as
functional inhibitors upon expression in cells or by
exogenous transduction into cells mediated by protein
transduction domains. This requires that the inhibition of
the target protein triggers a robust, recognizable cellular
phenotype [102, 103].
In a next step, the peptide ligand serves as a tool in a
high-throughput screen approach and the selection of
suitable molecules from a low molecular-weight compound
library. The Alpha Screen, an amplified luminescent
proximity homogeneous assay, is based on fluorescence
resonance and used to detect the interaction of two mole-
cules [104]. For this purpose, each one of the interaction
partners is being conjugated with dextran or hydrogel
beads that contain photosensitive molecules. The binding
of the partner molecules to each other brings the donor and
acceptor beads in close proximity. The donor bead is then
excited with a laser light of 680 nm, the energy is trans-
ferred from the donor bead to the acceptor beads via a
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reactive singlet oxygen, and a fluorescent signal of
520–620 nm can be measured. The addition of a low
molecular-weight compound able to disrupt the interaction
between the two partners leads to the extinction of the
emitted signal. The system can be formatted for high
throughput and complex compound libraries can be
screened. The compounds obtained in these in vitro assays
can be further investigated and their usefulness as drugs
can be assessed in cell culture. For this purpose, a related
technology, BiFC (bimolecular fluorescence complemen-
tation) can be used. It is based on the complex formation of
two fragments of a fluorescent dye, e.g., yellow fluorescent
protein (YFP). The two interacting partners, linked to the
YFP fragments, bring the fragments into immediate
vicinity of each other which leads to the reconstitution of
its fluorescent potential. This can be measured through
excitation at 513 nm and emission at 527 nm. Inhibitors of
the interaction would interfere with the fluorescence.
Interference with BiFC is a method that allows the detec-
tion of the disruption of an intracellular protein interaction,
a situation most favorable and suited for drug discovery
and development [105].
The identification of drug-like molecules from inter-
acting peptide sequences in appropriate screening assays
could lead to a significant extension of useful drug targets
and the discovery of suitable lead compounds.
6 Discussion
A large number of molecules have been identified that are
functionally involved in the etiology and progression of
cancer and which could serve as potential drug targets
[106]. The most promising among them are proteins that
are indispensable for the growth and survival of cancer
cells, but whose inactivation can be tolerated, at least for a
short time period, by normal cells [107]. The majority of
these ‘‘addiction’’ molecules, however, does not fit the
description of conventional drug targets. Such targets are
usually enzymes and receptors in which hydrophobic
amino acids form binding pockets allowing the access of
low molecular-weight compounds and the formation of
stable complexes. Proteins that do not exhibit these features
are usually considered as non-druggable. The development
of technologies that would allow the exploitation of the
large repertoire of molecules with crucial functional roles
in pathologic processes, but suboptimal characteristics of
conventional drug targets, would be of great value [108].
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Fig. 2 Peptide ligands and derivation of lead compounds for drug
development. Many proteins are structured in distinct functional
domains. Genetic analysis can reveal domains indispensable for, for
example, the growth and survival of cancer cells. Specific peptide
ligands able to recognize and suppress the functions of such crucial
domains and interaction surfaces can be derived through screening
assays in yeast cells. The peptides can be present in random peptide
libraries or cDNA libraries [101]. The interaction partners can be
functionally evaluated, they should bind and inhibit their target
proteins and, for example, should be able to induce cancer cell death
[111]. However, further technology development is required to turn
such ligands into useful drugs [20]. The technology comprises three
steps: (1) identification of a peptide ligand that specifically interacts
with a crucial functional domain of a target protein; (2) verification of
the functional consequences of ligand binding, e.g., induction of a
desired cellular phenotype upon intracellular interaction of the
peptide ligand with its target structure; and (3) replacement of the
peptide ligand with a functionally equivalent low molecular-weight,
drug-like compound and its optimization through medicinal chemis-
try. cDNA complementary DNA
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Survivin belongs to this class of drug targets. They are
obviously promising, but it is difficult to derive inhibitory
compounds against these targets. Survivin is an essential
component of multiple functional protein complexes in
cancer cells. It serves in collaboration with other proteins
in, for example, cell division, the regulation of apoptosis,
and cell motility. Since no small molecular-weight ligands
for survivin are known that could be used as lead com-
pounds, indirect strategies have been pursued. Insights into
the complex regulation of its expression, on the transcrip-
tional and post-transcriptional level, the secondary modi-
fications governing its subcellular location, protein
interactions and immunogenic properties have been con-
sidered and exploited as targets. The inhibition of signaling
pathways, transcription factors or protein modifying
enzymes, however, invariably has pleiotropic effects. The
side effects of such therapeutic agents are difficult or
impossible to predict. The use of drugs with a defined
target specificity, acting exclusively on the level of the
survivin protein, is therefore preferable. Specific peptide
ligands, able to recognize and suppress the functions of
crucial interaction surfaces of survivin, could pave the way.
One such peptide has been derived and shown to be able to
inhibit survivin function and induce cancer cell death.
However, similar to other biological macromolecules with
intracellular sites of action, these peptides are suboptimal
compounds when they are delivered systemically. The
technology to turn such peptide ligands into useful drugs is
being developed. They involve sequential screening pro-
cedures: first the identification of an inhibitory peptide
ligand, and subsequently the conversion of such a peptide
into a functionally equivalent small molecular-weight
compound. These strategies could result in a large exten-
sion of new drug targets and, more importantly, in a
plethora of beneficial drugs.
Constitutively activated signaling molecules have been
identified as drivers of cellular transformation and are the
favorite targets for therapeutics [69]. However, the inhi-
bition of such molecules is often counterbalanced by
pathway interconnections which result in adaptive resis-
tance and limited therapeutic responses [109, 110]. The
identification and inhibition of targets that are unable to
elicit adaptive responses seems crucial to achieve durable
clinical benefits. Survivin might well belong in this
category.
7 Conclusions
Survivin is distinguished by several functional properties
which are desirable for promising cancer drug targets. Its
expression occurs preferentially in cancer cells, but is
hardly detectable in normal tissues. It assumes functions
in different subcellular compartments and participates in
the control of cell division, apoptosis, the cellular stress
response, the regulation of cell migration, and metastasis
formation. Survivin expression serves as a biomarker,
high expression indicates an unfavorable prognosis and
resistance to chemotherapeutic agents and radiation
treatment. Despite these favorable properties, it has been
difficult to exploit the molecule as a drug target. The
structure of survivin does not reveal hydrophobic binding
pockets that could serve as docking sites for low molec-
ular-weight ligands. Several indirect approaches have
been exploited to affect its function and influence the
phenotype of survivin-expressing cells. Interference with
the expression of the survivin gene, the utilization of its
mRNA, the intracellular localization, the interaction with
binding partners, the stability of the survivin protein, and
the induction of survivin specific immune responses have
been experimentally explored. A direct strategy to inhibit
survivin has been recently pioneered, based on the iden-
tification of a specifically interacting peptide. This peptide
can recognize survivin intracellularly and cause the deg-
radation of the peptide ligand–survivin complex. Tech-
nology is being developed which utilizes the peptide
ligand–survivin interaction in high-throughput screening
assays and which might yield small-molecular weight,
drug-like compounds with functional properties of survi-
vin inhibitors.
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